A Proposal for an Alternative Approach to Particle Size Method Development During Early-Stage Small Molecule Pharmaceutical Development

J Pharm Sci. 2019 Nov;108(11):3515-3520. doi: 10.1016/j.xphs.2019.08.007. Epub 2019 Aug 21.

Abstract

Particle size analysis in the pharmaceutical industry has long been a source of debate regarding how best to define measurement accuracy; the degree to which the result of a measurement or calculation conforms to the true value. Defining a "true" value for the size of a particle can be challenging as the output of its measurement will differ because of variations in measurement approaches, instrumental differences and calculation methods. Consequently, for "real" particles, a universal "true" value does not exist and accuracy is therefore not a definable characteristic. Accordingly, precision is then a measure of the ability to reproducibly achieve a measurement of unknown relevance. This article proposes, in place of accuracy, a means to define the "appropriateness" of a measurement in line with the critical quality attributes (CQA) of the material being characterized. The decision as to whether the measurement is correct should involve a link to the CQA; that is, correlation should be demonstrated, without which the measured particle size cannot be defined as a critical material attribute. Correspondingly, methods should also be able to provide sufficient precision to demonstrate discrimination relating to variation in the CQA. The benefits and challenges of this approach are discussed.

Keywords: accuracy; control strategy; image analysis; materials science; multivariate analysis; particle size; quality.

MeSH terms

  • Drug Development / methods*
  • Drug Industry / methods
  • Particle Size
  • Pharmaceutical Preparations / chemistry*
  • Small Molecule Libraries / chemistry*

Substances

  • Pharmaceutical Preparations
  • Small Molecule Libraries